Low-pro­file eye drop de­vel­op­er spells out the game plan that drew Brent Saun­ders to the board — and it in­volves go­ing ear­li­er than an­ti-VEG­Fs

When Brent Saun­ders took on the chair­man role on OcuTer­ra Ther­a­peu­tics’ board of di­rec­tors a few months ago — his first biotech gig since sell­ing Al­ler­gan to Ab­b­Vie — he drew at­ten­tion to a start­up that wasn’t quite ready for it. The web­site of­fered a glimpse of the lead­er­ship team, a lead drug, but not much else.

That’s chang­ing now.

OcuTer­ra is step­ping in­to the lime­light with the fi­nal close of a $35 mil­lion Se­ries B, which is de­signed to fund a Phase II tri­al of its lead eye drop and there­by nail down proof of con­cept for what it calls a non-in­va­sive op­tion for a siz­able swath of pa­tients at the ear­ly stages of di­a­bet­ic reti­nal dis­ease and wet age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER